Diseases

WHO advocates fully oral regimens to treat people with multidrug-resistant tuberculosis

By Staff Writer

March 21, 2019

The World Health Organization (WHO) has announced that it is recommending shifting to a new treatment course in which drugs will be taken through the mouth, to treat people with multidrug-resistant tuberculosis (MDR-TB).

In a statement, the global health body said fully oral regimen is more effective and is less likely to provoke adverse side effects.

Nigeria is one of the countries in the world where weight-based injectable anti-TB drugs are part of the country’s TB treatment guidelines.

The recommendations are part of a larger package of actions designed to help countries increase the pace of progress to end tuberculosis (TB) and released in advance of World TB Day.“The theme of this year’s World TB Day is: It’s time to end TB,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “We’re highlighting the urgent need to translate commitments made at the 2018 UN High Level Meeting on TB into actions that ensure everyone who needs TB care can get it.”

Since 2000, 54 million lives have been saved, and TB deaths fell by one-third.  But 10 million people still fall ill with TB each year, with too many missing out on vital care.   The WHO package is designed to help countries close gaps in care ensuring no one is left behind. Key elements include:

“This is a set of pragmatic actions that countries can use to accelerate progress and act on the high-level commitments made in the first-ever UN High Level Meeting on TB last September,” said Dr Tereza Kasaeva, Director WHO’s Global TB Programme.

TB is the world’s top infectious disease killer, claiming 4 500 lives each day. The heaviest burden is carried by communities facing socio-economic challenges, those working and living in high-risk settings, the poorest and marginalized.